ArticleCurrent oncology (Toronto, Ont.)2016

Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Ma Kim Anh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.